Date | Insider | Price | Amount |
---|---|---|---|
3-23-2023 Insider Buy |
David Drutz Director |
$4.27 CAGR » |
$38,430.00 9,000 shares |
8-15-2023 Insider Buy |
David Drutz Director |
$2.88 CAGR » |
$862.50 300 shares |
3-24-2023 Insider Buy |
Richard I. Eisenstadt Chief Financial Officer |
$4.31 CAGR » |
$43,140.00 10,000 shares |
3-23-2023 Insider Buy |
Matthew Scott Harris Chief Medical Officer |
$4.22 CAGR » |
$42,200.00 10,000 shares |
6-15-2022 Insider Buy |
David Drutz Director |
$8.00 CAGR » |
$8,000.00 1,000 shares |
5-24-2022 Insider Buy |
David Drutz Director |
$4.50 CAGR » |
$5,400.00 1,200 shares |
12-10-2020 Insider Buy |
Klaus Schafer Director |
$11.99 CAGR » |
$23,980.00 2,000 shares |
6-15-2020 Insider Buy |
Venrock Healthcare Capital Partners III, L.P. >10% Owner |
$7.54 CAGR » |
$11,310,000.00 1,500,000 shares |
5-28-2020 Insider Buy |
Venrock Healthcare Capital Partners III, L.P. >10% Owner |
$8.74 CAGR » |
$11,395,493.13 1,303,636 shares |
9-5-2019 Insider Buy |
Vipin K. Garg President and CEO |
$2.10 CAGR » |
$42,000.00 20,000 shares |
10-9-2018 Insider Buy |
Wayne Pisano Director |
$4.59 CAGR » |
$9,180.00 2,000 shares |
6-6-2017 Insider Buy |
M. Scot Roberts Chief Scientific Officer |
$4.42 CAGR » |
$1,984.58 449 shares |
5-25-2018 Insider Buy |
William Enright President and CEO |
$0.51 CAGR » |
$659.88 1,300 shares |
12-27-2017 Insider Buy |
Derace L. Schaffer Director |
$1.76 CAGR » |
$259,356.40 147,130 shares |
12-7-2017 Insider Buy |
Derace L. Schaffer Director |
$1.78 CAGR » |
$42,303.53 23,745 shares |
12-5-2017 Insider Buy |
Derace L. Schaffer Director |
$1.79 CAGR » |
$46,587.57 26,010 shares |
11-30-2017 Insider Buy |
Derace L. Schaffer Director |
$1.91 CAGR » |
$63,638.65 33,315 shares |
11-27-2017 Insider Buy |
Derace L. Schaffer Director |
$2.03 CAGR » |
$44,282.19 21,808 shares |
11-21-2017 Insider Buy |
Derace L. Schaffer Director |
$2.08 CAGR » |
$38,214.73 18,331 shares |
8-25-2017 Insider Buy |
Derace L. Schaffer Director |
$2.25 CAGR » |
$151,281.67 67,326 shares |
8-23-2017 Insider Buy |
Derace L. Schaffer Director |
$2.21 CAGR » |
$110,263.47 50,000 shares |
6-2-2017 Insider Buy |
John Gill Director |
$4.34 CAGR » |
$4,343.50 1,000 shares |
Also See: Institutional Holders of ALT
Also See: SEC filings
Growth of $10,000.00 Without Dividends Reinvested |
||
Start date: | 03/24/2023 | |
End date: | 04/24/2024 | |
Start price/share: | $4.32 | |
End price/share: | $7.08 | |
Dividends collected/share: | $0.00 | |
Total return: | 63.89% | |
Average Annual Total Return: | 57.49% | |
Starting investment: | $10,000.00 | |
Ending investment: | $16,388.77 | |
Years: | 1.09 |
Altimmune Insider Buying
This Holdings Channel page has presented insider buying activity, covering Directors, officers (such as CEO, CFO, COO, etc.), and >10% owners (who are required to file form 4's with the SEC). Important institutional owners may not fall under these categories, but instead file their holdings quarterly on the latest form 13F filings. While recent Altimmune insider buying activity is included, there may also be stock sales over this same period (Also See: SEC filings for sales and other details).
Also See: Funds Holding ALT
Free ALT Email Alerts: Get Dividend Alerts Get SEC Filing Alerts |
Other companies seeing insider buying close in time to when the Altimmune Insider Buying occurred are:
Verrica Pharmaceuticals Insider Buying |